News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma.

Al's Comment:

 This researcher is saying that combining 3 immunotherapies resulted in dramatic survivals in mice and wants to try it in humans with GBM.   This is one of the most promising avenues of research. The drugs are available (in trials for other cancers).  These researchers have asked us to fund the trial, but we did not have enough money to do so.   The only thing holding up the trial is funding.  If anyone wants to help us fund this, contact us!


Posted on: 08/17/2014

Oncoimmunology. 2014 May 15;3:e28927. eCollection 2014.
Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma.
Wainwright DA, Lesniak MS.
Author information: 
The Brain Tumor Center; The University of Chicago Pritzker School of Medicine; Chicago, IL USA.
 
Abstract
Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical trial.
 
 PMID: 25057450 [PubMed] 
 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740